WT 2725

Drug Profile

WT 2725

Alternative Names: WT-2725

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Osaka University School of Medicine
  • Developer Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals
  • Class Antineoplastics; Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Haematological malignancies; Solid tumours

Most Recent Events

  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 31 Jul 2013 Phase-I clinical trials in Haematological malignancies in USA (Parenteral)
  • 08 Apr 2013 WT 2725 is in phase I development for Solid tumours (late-stage disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top